Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig
Mohamed Elsafy, Drug Safety and Pharmacovigilance Lead Physician, Global Safety Strategy and Governance at ClinRM LLC, shared a post on LinkedIn:
”Sutacimig represents a novel and potentially transformative approach in Glanzmann thrombasthenia, shifting the paradigm from reactive bleeding management to true prophylaxis.
By leveraging a bispecific mechanism to localize and stabilize endogenous Factor VIIa at the platelet surface, this strategy directly addresses the underlying hemostatic defect. Early data showing meaningful reductions in bleeding burden are encouraging, particularly in a setting with no established preventive options.
If sustained in later-stage studies, this could redefine the standard of care in rare platelet disorders.”
Stay updated with Hemostasis Today.
-
Apr 7, 2026, 16:03Frits Rosendaal Is The 2026 Recipient of the ISTH Robert P. Grant Medal
-
Apr 7, 2026, 16:02Support the WHO Resolution On Stroke and Set A Clear Path to Action – World Stroke Organization
-
Apr 7, 2026, 16:00Amit Saraswat: The Role of Physiotherapy in Regaining Independence In Stroke Recovery
-
Apr 7, 2026, 15:59David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation
-
Apr 7, 2026, 15:58Armghan Ans: The 2026 Stroke Guidelines and the Clinical Logic Gap in AI Tools
-
Apr 7, 2026, 15:55Louise St. Germain Bannon: A Call to Advance Health Equity for Women on World Health Day
-
Apr 7, 2026, 15:54Emicizumab In a Preterm Infant with Severe Hemophilia A – RPTH
-
Apr 7, 2026, 15:45Alejandro Lusilla Lopez: PRF for Complex Anal Fistulae Outcomes
-
Apr 7, 2026, 15:41Edwin Ofori Atta: High-Dose Vitamin C and Vascular Function